Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation

NCT04531046 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Lymphoma Refractory
B-cell Lymphoma Recurrent

Interventions

DRUG: axicabtagene ciloleucel

Sponsor

The Lymphoma Academic Research Organisation